Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

NCT00159250 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
7
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Imperial College London

Collaborators